ANDA Approvals Soar, But Does FDA Need To Do More?
This article was originally published in The Pink Sheet Daily
Executive Summary
Industry consultant suggests that Office of Generic Drugs has to boost its approval volume even higher if it wants to cut its increasing workload.
You may also be interested in...
FDA's Generic Approvals Catch A Bit Of Breath In July But Continue At Fast Pace
US Generic drug approvals drop in July, but still are above the monthly average for the year, potentially signaling a new expected output.
FDA's Generic Approvals Catch A Bit Of Breath In July But Continue At Fast Pace
US Generic drug approvals drop in July, but still are above the monthly average for the year, potentially signaling a new expected output.
ANDA Approvals Break Record, May Set New Normal
FDA's June approval total is highest of GDUFA era, but does it signal a new elevated productivity level for the generics program?